Detalhe da pesquisa
1.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Invest New Drugs
; 41(2): 284-295, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36867316